Impact of interventions by a community pharmacist on care burden for people with dementia: development and randomized feasibility trial of an intervention protocol.
Caregiver burden
Community pharmacist
Dementia
Journal
Pilot and feasibility studies
ISSN: 2055-5784
Titre abrégé: Pilot Feasibility Stud
Pays: England
ID NLM: 101676536
Informations de publication
Date de publication:
02 Jun 2022
02 Jun 2022
Historique:
received:
18
09
2021
accepted:
17
05
2022
entrez:
2
6
2022
pubmed:
3
6
2022
medline:
3
6
2022
Statut:
epublish
Résumé
Traditionally, the role of pharmacists has been to manage and monitor pharmacotherapy for patients with dementia. However, additional intervention by community pharmacists to collect and share patient information with other professionals may help reduce the care burden among caregivers. The aims of this study were to examine (1) the feasibility of a designed community pharmacist working procedure in dementia care and (2) the expected impact of pharmacist intervention on care burden. This was a randomized, open-label, parallel-group feasibility study, involving eight Nara City pharmaceutical association member pharmacies that provided consent to participate. These pharmacies were assigned to an intervention group or a control group at a 1:1 ratio. The subjects were patients with dementia and their primary caregivers that visited the participating pharmacies and provided consent to participate. Pharmacists in the intervention group actively collected information from the patients' family physicians and care managers and intervened to address medication-related problems, while those in the control group only performed their normal duties. The primary endpoint was a change in the caregiver's score on the Japanese version of Zarit Caregiver Burden interview (J-ZBI) from the baseline to after 5 months of follow-up. The changes in mean J-ZBI scores from the beginning to the end of the study period of the two groups were compared. Obtaining consent from caregivers was certainly difficult, but possible. Pharmacists managed to fill out the survey form while practising pharmaceutical care. Totally, nine patients and nine caregivers in the intervention group and nine patients and eight caregivers in the control group completed the study. The changes in J-ZBI scores could be calculated for seven cases in the intervention group and five cases in the control group. The J-ZBI scores were found to decrease by 1.0 in the intervention group and increase by 3.0 in the control group. The protocol presented was considered feasible, but, the intervention process needs to be simplified in order to conduct a large study. Also, improvements are needed in the various survey forms and in the explanatory documents for caregivers. Although the sample size was small, the effect sizes suggested that community pharmacist interventions for patient with dementia may reduce the care burden for caregivers. UMIN000039949 (registration date: 1 April 2020, retrospectively registered).
Sections du résumé
BACKGROUND
BACKGROUND
Traditionally, the role of pharmacists has been to manage and monitor pharmacotherapy for patients with dementia. However, additional intervention by community pharmacists to collect and share patient information with other professionals may help reduce the care burden among caregivers. The aims of this study were to examine (1) the feasibility of a designed community pharmacist working procedure in dementia care and (2) the expected impact of pharmacist intervention on care burden.
METHODS
METHODS
This was a randomized, open-label, parallel-group feasibility study, involving eight Nara City pharmaceutical association member pharmacies that provided consent to participate. These pharmacies were assigned to an intervention group or a control group at a 1:1 ratio. The subjects were patients with dementia and their primary caregivers that visited the participating pharmacies and provided consent to participate. Pharmacists in the intervention group actively collected information from the patients' family physicians and care managers and intervened to address medication-related problems, while those in the control group only performed their normal duties. The primary endpoint was a change in the caregiver's score on the Japanese version of Zarit Caregiver Burden interview (J-ZBI) from the baseline to after 5 months of follow-up. The changes in mean J-ZBI scores from the beginning to the end of the study period of the two groups were compared.
RESULTS
RESULTS
Obtaining consent from caregivers was certainly difficult, but possible. Pharmacists managed to fill out the survey form while practising pharmaceutical care. Totally, nine patients and nine caregivers in the intervention group and nine patients and eight caregivers in the control group completed the study. The changes in J-ZBI scores could be calculated for seven cases in the intervention group and five cases in the control group. The J-ZBI scores were found to decrease by 1.0 in the intervention group and increase by 3.0 in the control group.
CONCLUSIONS
CONCLUSIONS
The protocol presented was considered feasible, but, the intervention process needs to be simplified in order to conduct a large study. Also, improvements are needed in the various survey forms and in the explanatory documents for caregivers. Although the sample size was small, the effect sizes suggested that community pharmacist interventions for patient with dementia may reduce the care burden for caregivers.
TRIAL REGISTRATION
BACKGROUND
UMIN000039949 (registration date: 1 April 2020, retrospectively registered).
Identifiants
pubmed: 35655244
doi: 10.1186/s40814-022-01071-7
pii: 10.1186/s40814-022-01071-7
pmc: PMC9161485
doi:
Types de publication
Journal Article
Langues
eng
Pagination
118Informations de copyright
© 2022. The Author(s).
Références
Int Nurs Rev. 2015 Sep;62(3):340-50
pubmed: 26058542
Aging Ment Health. 2011 Aug;15(6):663-70
pubmed: 21547745
Curr Psychiatry Rep. 2017 Aug 10;19(9):64
pubmed: 28795386
Psychiatry Clin Neurosci. 2004 Dec;58(6):606-10
pubmed: 15601384
Yakugaku Zasshi. 2001 Mar;121(3):221-32
pubmed: 11265117
BMJ. 2016 Oct 24;355:i5239
pubmed: 27777223
J Am Pharm Assoc (2003). 2003 Sep-Oct;43(5 Suppl 1):S20-1
pubmed: 14626518
Int J Clin Pract. 2014 Apr;68(4):465-70
pubmed: 24588972
Int J Clin Pharm. 2017 Jun;39(3):495-506
pubmed: 28315115
Pharmacy (Basel). 2018 Aug 20;6(3):
pubmed: 30127287
J Grad Med Educ. 2012 Sep;4(3):279-82
pubmed: 23997866
Patient Prefer Adherence. 2014 Sep 15;8:1223-8
pubmed: 25258516
Psychiatry Clin Neurosci. 1997 Oct;51(5):281-7
pubmed: 9413874
BMJ Open. 2016 Mar 16;6(3):e010278
pubmed: 26983947
Int Psychogeriatr. 2014 Nov;26(11):1875-83
pubmed: 25104063
Int J Clin Pharm. 2017 Aug;39(4):641-656
pubmed: 28555421
Gerontologist. 2002 Jun;42(3):356-72
pubmed: 12040138
Aging Ment Health. 2019 Oct;23(10):1333-1339
pubmed: 30460856
Alzheimers Dement (N Y). 2020 May 06;6(1):e12010
pubmed: 32377557
Pharm Pract (Granada). 2015 Apr-Jun;13(2):521
pubmed: 26131040
Int Psychogeriatr. 2016 Feb;28(2):221-31
pubmed: 26478530
Dementia (London). 2013 Nov;12(6):734-50
pubmed: 24337637
Yakugaku Zasshi. 2015;135(9):1057-67
pubmed: 26329552
Res Social Adm Pharm. 2016 Nov - Dec;12(6):815-829
pubmed: 26797263
Int J Pharm Pract. 2020 Jun;28(3):233-245
pubmed: 31621974
JBI Database System Rev Implement Rep. 2015 Nov;13(11):52-63
pubmed: 26657464
BMC Psychiatry. 2019 Jan 14;19(1):23
pubmed: 30642300
J Aging Health. 2020 Oct;32(9):1198-1213
pubmed: 31957536
Biosci Trends. 2018;12(5):520-522
pubmed: 30473563
Geriatr Psychol Neuropsychiatr Vieil. 2019 Mar 1;17(1):7-19
pubmed: 30907370
Aging Ment Health. 2006 Mar;10(2):79-86
pubmed: 16517482
Shinrigaku Kenkyu. 1999 Aug;70(3):203-10
pubmed: 10629918
Psychogeriatrics. 2018 May;18(3):166-174
pubmed: 29409158